Inositol 1,4,5-trisphosphate-gated calcium channel ITPR1 (UniProt: Q14643; also known as IP3 receptor isoform 1, IP3R 1, InsP3R1, Inositol 1,4,5 trisphosphate receptor, Inositol 1,4,5-trisphosphate receptor type 1, Type 1 inositol 1,4,5-trisphosphate receptor, Type 1 InsP3 receptor) is encoded by the ITPR1 (also known as INSP3R1) gene (Gene ID: 3708) in human. InsP3R1 is a multi-pass membrane protein located on endoplasmic reticulum (ER) membrane. Its highest levels are found in neurons, with very high expression in the Purkinje cells of the cerebellum. InsP3R1 contains a calcium channel in its C-terminal extremity. It has a large N-terminal cytoplasmic region that has the ligand-binding site in the N-terminus and modulatory sites in the middle portion immediately upstream of the channel region. InsP3R1 serves as an intracellular channel that mediates calcium release from the endoplasmic reticulum following stimulation by inositol 1,4,5-trisphosphate. It is involved in the regulation of epithelial secretion of electrolytes and fluid through the interaction with AHCYL1. It also plays a role in ER stress-induced apoptosis wherein cytoplasmic calcium released from the ER triggers apoptosis by the activation of CaM kinase II, eventually leading to the activation of downstream apoptosis pathways. InsP3R1 is phosphorylated by cAMP-dependent protein kinase (PKA), which increases the interaction with inositol 1,4,5-trisphosphate and reduces the interaction with AHCYL1. This prevents the ligand-induced opening of the calcium channels. Calcium appears to inhibit ligand binding to the receptor, most probably by interacting with a distinct calcium-binding protein which then inhibits the receptor. Reduced expression of InsP3R1 has been reported in cisplatin-resistant cancer cells and overexpression of InsP3R1 in resistant cells induces apoptosis and increases sensitivity to cisplatin. Mutations or altered expression of IP3R1 can lead to aberrant Ca²⁺ signaling, contributing to conditions such as spinocerebellar ataxia, Alzheimer′s disease, Huntington′s disease, heart failure, stroke and cancer. (Ref.: Baker, MR., et al. (2023). Cell Calcium. 114:102770; Tsunoda T., et al. (2005). Oncogene. 24(8):1396-402; Wang, Y., et al. (2001). Cir. Res. 88(2): 202-209).

We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 4H8 is a ZooMAb^® recombinant rabbit monoclonal antibody that specifically detects IP3R1. It targets an epitope within 24 amino acids from the first cytoplasmic domain.

KLH-conjugated linear peptide corresponding to 24 amino acids from the N-terminal, first cytoplasmic domain of human IP3R1.

Quality Control Testing

Evaluated by Western Blotting in HeLa cell lysate.

Western Blotting Analysis: A 1:10,000 dilution of this antibody detected IP3R1 in HeLa cell lysate.

Tested Applications

Western Blotting Analysis: A 1:10,000 dilution from a representative lot detected IP3R1 in lysates from human brain, mouse brain, and rat brain tissues.

Affinity Binding Assay: A representative lot of this antibody bound IP3R1 peptide with at least one thousand-fold (1,000X) higher affinity than with non-specific control peptide.

Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected IP3R1 in human cerebellum tissue sections.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.